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Flickering light dilates retinal arterioles and increases retinal blood ﬂow, a response termed
functional hyperemia. This response is diminished in diabetic patients even before the
appearance of overt clinical retinopathy. The loss of functional hyperemia could deprive
retinal neurons of oxygen and nutrients, possibly exacerbating the development of dia-
betic retinopathy.We have tested whether inhibiting inducible nitric oxide synthase (iNOS)
reverses the loss of functional hyperemia in diabetic rat retinas in vivo. Changes in retinal
arteriole diameter were measured following diffuse ﬂickering light stimulation in control
rats, streptozotocin-induced type 1 diabetic rats and diabetic rats treated with aminoguani-
dine (AG; an iNOS inhibitor), either acutely via IV injection or chronically in drinking water.
Flickering light-evoked large arteriole dilations (10.8±1.1%) in control rats.This response
was diminished by 61% in diabetic animals (4.2±0.3%). Both acute and chronic treatment
withAG restored ﬂicker-induced arteriole dilations in diabetic rats (8.8±0.9 and 9.5±1.3%,
respectively).The amplitude of the corneal electroretinogram b-wave was similar in control
and diabetic animals. These ﬁndings demonstrate that inhibiting iNOS with AG is effec-
tive in preventing the loss of, and restoring, normal functional hyperemia in the diabetic
rat retina. Previous work has demonstrated the efﬁcacy of iNOS inhibitors in slowing the
progression of diabetic retinopathy. This effect could be due, in part, to a restoration of
functional hyperemia.
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INTRODUCTION
Diabetic retinopathy, a leading cause of blindness in the devel-
oped world, has a complex pathology that affects both neuronal
and vascular elements of the retina (Mizutani et al., 1996; Bar-
ber et al., 1998; Antonetti et al., 2006; Fletcher et al., 2007). In
the healthy retina, ﬂickering light induces dilation of retinal ves-
sels and an increase in blood ﬂow, a response termed functional
hyperemia. This response brings additional oxygen and nutrients
tomeettheincreasedmetabolicdemandsof activeneurons(Polak
et al., 2002; Riva et al., 2005). A reduction in functional hyper-
emia is one of the earliest retinal changes observed in diabetic
patients (Garhofer et al., 2004; Mandecka et al., 2007; Bek et al.,
2008; Nguyen et al., 2009; Pemp et al., 2009). The cause and the
possible consequences of this reduction in ﬂicker-induced vasodi-
lation are not known,although it could possibly contribute to the
development of diabetic retinopathy.
We have previously shown that nitric oxide (NO) modulates
neurovascular signaling pathways in the retina. Both light and
glial stimulation evoke retinal vasodilation when NO levels are
low, but vasodilation is reduced and vasoconstriction enhanced
when NO levels are raised (Metea and Newman, 2006). Inter-
estingly, several laboratories have shown an upregulation of the
inducible form of nitric oxide synthase (iNOS) in the diabetic
retina (Du et al., 2002; Mishra and Newman, 2010), leading to
h i g hN Ol e v e l s( Kowluru et al., 2000). This increase in tissue NO
concentration could alter neuron-to-vessel signaling, leading to
reduced functional hyperemia in diabetic patients.
Aspeciﬁcinhibitorof iNOS,aminoguanidine(AG),hasindeed
been shown to slow the progression of diabetic retinopathy in
humans and in animal models of diabetes (Kern and Engerman,
2001; Bolton et al., 2004). These beneﬁcial effects of AG have
largely been attributed to the inhibition of advanced glycation
end-product (AGE) formation (Brownlee et al., 1986). However,
ﬁndingsfrommultiplestudiessuggestthatAGcouldalsobeacting
by inhibiting iNOS (Kern et al., 2000; Kowluru et al., 2000; Kern
and Engerman, 2001; Mishra and Newman, 2010), especially in
early stages of the disease.
Using a streptozotocin-induced rat model of type 1 diabetes,
we have now examined whether AG can reverse the disruption of
functional hyperemia in the retinas of diabetic rats in vivo.W e
ﬁnd that ﬂicker-induced arteriole dilation is substantially reduced
in diabetic rat retinas,as it is in patients with diabetic retinopathy.
This reduction can be reversed by administering AG to the dia-
beticrats,eitheracutelyviaIVinjectionorchronicallyindrinking
water.
MATERIALS AND METHODS
This study was approved by the University of Minnesota Institu-
tionalAnimal Care and Use Committee according to the National
Institutes of Health Guidelines for experimental animals.
INDUCTION OF DIABETES
Two month old male Long–Evans rats (Harlan) were made dia-
betic by injecting streptozotocin (STZ; 70mg/kg in citrate buffer,
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IP; Sigma; Mishra and Newman, 2010). Successful induction
of diabetes (blood glucose>250mg/dl; OneTouch Ultra, Life-
Scan) was tested 3days later. Animals were given supplemental
insulin (1.5U Lantus insulin glargine subcutaneously, thrice a
week;sanoﬁ-aventisU.S.)aspreviouslydescribed(Duetal.,2002).
Blood glucose during the course of diabetes, monitored biweekly,
averaged 535±16mg/dl (29.7±0.9mmol/l) for diabetic rats and
543±12mg/dl (30.2±0.7mmol/l) for diabetic rats treated with
aminoguanidine (Sigma) in drinking water.
IN VIVO RAT PREPARATION
The in vivo rat preparation has been described previously (Sri-
enc et al., 2010). Surgery was performed under 2% isoﬂurane
anesthesia. Core body temperature was continuously monitored
andmaintainedat37˚C(TC-1000TemperatureController,CWE).
The left femoral vein and artery were cannulated for drug admin-
istration and monitoring of blood pressure, respectively, and a
tracheotomy performed for artiﬁcial ventilation. The animal was
placed in a modiﬁed stereotaxic holder and the right pupil dilated
with 1% atropine sulfate (Alcon Laboratories). Corneal refraction
wasneutralizedwithgonioscopicprismsolutionandacontactlens
(5.4mmfunduslens,OcularInstruments).Theholdercontaining
the rat was placed below an upright microscope.
Anesthesia was maintained during the experiment by continu-
ously infusing α-chloralose-HBC-complex (55mg/kg/h; Sigma).
Animals were artiﬁcially ventilated (30–50breaths/min; CWE
SAR-830-P) and paralyzed with gallamine triethiodide (20mg/kg
bolus; 20mg/kg/h; Sigma) to prevent eye movements. Mean arte-
rial blood pressure (MABP), blood oxygen saturation (sO2), and
pHweremaintainedwithinphysiologicallimits(100–125mmHg,
92–97%,and7.35–7.45,respectively).MABPandsO2 werenotdif-
ferent between experimental groups: control, 111.3±2.8mmHg
and 95.7±0.8%; diabetic, 122.2±4.4mmHg and 92.7±1.5%;
diabetic treated with AG IV, 115.4±1.1mmHg and 95.2±0.8%;
and diabetic treated with AG in water, 116.6±2.5mmHg and
94.8±0.6% (P >0.05). Following experiments, animals were
euthanized by IV injection of 40mM KCl (1ml/kg).
LIGHT STIMULATION
Retinalphotoreceptorswerestimulatedwitha12Hzﬂickeringdif-
fuse white light (Riva et al., 2005). Stimulus trials were separated
by 2min periods in the dark. Light from a ﬁber optic illuminator
was gated with an electromechanical shutter and focused onto the
globeata45˚anglethroughaﬁberbundle.Theilluminanceof the
light was 12klux at the surface of the globe.
MEASUREMENT OF FLICKER-INDUCED DILATION
The retina was imaged with a 4× objective and an Olympus
FluoView 1000 laser scanning confocal microscope. Blood vessels
were labeled by IV injection of dextran ﬂuorescein isothiocyanate
(2,000,000MW, 3% solution, 1–3ml; Sigma). The luminal diam-
eters of ﬁrst order arterioles were measured with confocal line
scans drawn perpendicular to the vessel (Srienc et al., 2010) and
luminal diameter vs. time graphs calculated with a custom Mat-
Labroutine.Flicker-induceddilationswerecomposedof transient
and sustained phases. Response amplitude was measured using
the ﬁrst transient peak and the three largest responses averaged
to calculate peak response. Diabetic animals developed partial
cataracts, a common occurrence in STZ-treated animals (Perry
et al., 1987). These cataracts did not interfere with line scan mea-
surements of vessel diameter but prevented us from using laser
speckle ﬂowmetry (Srienc et al.,2010) to monitor blood velocity.
ELECTRORETINOGRAM MEASUREMENT
The corneal electroretinogram (ERG) electrode was attached to
the center of a custom-made plastic light diffuser placed over the
cornea. The reference electrode was placed under the skin on the
right cheek, 1cm from the eye. The retina was dark-adapted for
15min prior to recording ERGs. Ten millisecond ﬂashes of dif-
fuse white light were focused onto the diffuser. A series of ﬂashes
(intensities−3to0logunits)wasemployedtodeterminetheERG
b-wave intensity-response relation,with 0 log unit corresponding
to an illuminance of 120klux at the surface of the diffuser. ERGs
were averaged to improve signal-to-noise ratio. Animals display-
ing noisy ERGs were excluded from analysis. ERGs were ﬁltered
(1–100Hz bandpass) and b-wave amplitude was measured from
the negative a-wave trough to the positive b-wave peak.
STATISTICS
One-way ANOVA followed by one-tailed Dunnett’s post hoc test
was used to calculate statistical signiﬁcance for percent dilation
data and two-tailed Dunnett’s post hoc test for resting diame-
ter data. Homoscedastic two-tailed Student’s t-test was used to
compare ERG data. Data presented as mean±SEM. α=0.05.
RESULTS
We evaluated ﬂicker-induced retinal arteriole dilation in vivo in
diabetic and age-matched control rats. Experiments were con-
ducted7monthsafterinductionofdiabetes.Theretinawasstimu-
latedwithadiffuse12Hzﬂickeringlightandtheluminaldiameter
of arterioles measured with confocal line scans (Figure1). In age-
matched control animals, light stimulation evoked pronounced
arteriole dilations composed of an initial transient dilation fol-
lowedbyasustainedresponse(Figure2).Flicker-evokeddilations
in control retinas averaged 10.8±1.1% (n =6; summarized in
Figure 3A). The dilatory response was greatly diminished in dia-
betic animals (Figure 2), where responses averaged 4.2±0.3%
(n =6), only 39% of control responses (P <0.001; Figure 3A).
Increased tissue concentration of NO, resulting from iNOS
upregulation, may be responsible for the reduction in ﬂicker-
induced dilations. We thus evaluated the effect of the iNOS
inhibitor AG on ﬂicker-induced arteriole dilations in vivo.A G
was administered in two ways. We injected AG intravenously
(100mg/kg) to test the effect of acute AG treatment. Flicker-
induced changes in arteriole diameter were measured within 4h
of AG injection. We also tested the effect of chronic AG treatment
by adding AG to the drinking water of diabetic rats (500mg/l;
Hammes et al.,1991) starting 1week after successful induction of
diabetes and continuing until the experiments were conducted.
Both treatment paradigms reversed the loss of ﬂicker-induced
arteriole dilation in diabetic animals (Figure 2). Flicker-induced
dilations in the AG treatment groups averaged 8.8±0.9% (n =3)
for IV administration and 9.5±1.3% (n =7) for drinking water
administration,bothsigniﬁcantlylargerthaninuntreateddiabetic
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FIGURE 1 | Measurement of ﬂicker-induced changes in retinal arteriole
diameter using confocal line scans. (A) Low power confocal image of
retinal vessels. Arterioles (a) can be distinguished from venules (v) by their
branching pattern and relative size.The diameter of the arteriole was
measured with confocal line scans (white line). Scale bar, 250μm. (B) High
magniﬁcation image of the boxed area in A showing the region of the arteriole
where line scans were taken. Scale bar, 25μm. (C) Segments of a line scan
image from the arteriole in (B).The vertical bars in (D) indicate the times at
which the three segments were taken. Distance is represented vertically
(scale bar, 25μm) and time horizontally (scale bar, 100ms). A diffuse ﬂickering
light-evoked vessel dilation, indicated by the widening of the vessel in
segment 2. (D)Time course of the ﬂicker-induced arteriole dilation.The onset
of the ﬂickering light (black bar at bottom) evoked an initial transient dilation
followed by a smaller secondary dilation.
rats (P <0.02;Figure3A). Neither treatment group differed from
controls (P >0.2).
Thelossofneurovascularcouplingobservedindiabeticanimals
could be due to a change in the resting diameter of the arteri-
oles. Vessels that are more dilated at rest would not be able to
dilate as much in response to light. However, there was no signif-
icant difference in the average resting arteriole diameter between
groups in our study. The resting diameter of retinal arterioles was
32.7±1.4μm( n =6) in control animals, 35.6±2.0μm( n =6)
in diabetic animals (P >0.7), and 29.3±7.6μm( n =3; P >0.7)
and 34.8±2.1μm( n =7; P >0.8) in diabetic animals treated
with AG IV and in drinking water, respectively (Figure 3B). The
smaller ﬂicker-evoked vasodilation observed in diabetic retinas
wasindependentoftherestingarteriolediameter,asdemonstrated
by a scatter plot of percent dilation vs. resting arteriole diameter
(Figure 3C).
AG treatment could affect ﬂicker-induced dilations in con-
trols animals, but this was not the case in our experiments.
AG administration had no effect on ﬂicker-induced dilations in
controls. Vasodilations averaged 10.0±0.8% (n =7; P >0.3) for
IV administration and 9.6±0.4% (n =6; P >0.2) for drink-
ing water administration (Figure 3D). AG was administered in
drinking water for 2months prior to experiments. The rest-
ing arteriolar diameter of control animals treated with AG
acutely (via IV injection) was 34.5±2.1μm( n =7; P >0.6)
and chronically (in drinking water) was 37.9±1.8μm( n =6;
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FIGURE 2 | Flicker-induced dilation of retinal arterioles in control and
diabetic animals. A diffuse ﬂickering light (black bar at bottom) evoked a
prominent arteriole dilation in a control animal, but a much smaller dilation
in a diabetic animal.Treatment with the iNOS inhibitor aminoguanidine (AG)
restored ﬂicker-induced arteriole dilations in diabetic animals to control
levels when given intravenously (diabetic AG-IV), or in drinking water
(diabetic AG-H2O).
P =0.1), neither statistically different from untreated controls
(Figure 3E).
The loss of neurovascular coupling could also be due to a
decrease in light-evoked neuronal activity in diabetic animals,
caused either by a loss of neuronal responsiveness or by neu-
ronal death. We evaluated retinal responsiveness by monitoring
the b-wave of the ERG, which primarily reﬂects ON bipolar
cell activity. A series of ERGs were recorded to light ﬂashes of
increasing intensities (Figure 4A). There was no difference in the
maximalb-waveamplitudebetweencontrolanddiabeticanimals:
0.22±0.01mV (n =7) vs. 0.24±0.03mV (n =3), respectively
(P >0.4; Figures 4B,C). The sensitivity of the retina, evaluated
bythelightintensitythatevokedahalf-maximalb-waveresponse,
was also similar: 0.012±0.003 in controls vs. 0.014±0.007 in
diabetic rats (P >0.7, where an intensity value of 1 corresponds
to 0 log unit intensity; Figures 4B,D). These results indicate that
overall neuronal activity was not reduced in the retinas of our
diabetic rats.
DISCUSSION
Our results demonstrate that the iNOS inhibitor AG, delivered
either IV or in drinking water, reverses the loss of functional
hyperemia in an animal model of type 1 diabetes. Although AG
also inhibits the formation of AGEs (Brownlee et al., 1986), it
is likely that AG acts to restore functional hyperemia by block-
ing iNOS. Our ﬁndings demonstrate that the loss of light-evoked
vasodilation is reversed within 4h following IV administration of
AG.AG could not act this rapidly if it functioned by reducing for-
mation of AGEs. In addition, we showed previously that the loss
of light-evoked vasodilations in an ex vivo isolated retina prepara-
tion were also restored rapidly by AG, within 30min (Mishra and
Newman, 2010). A second selective iNOS inhibitor, 1400W, was
also effective in reversing the loss of functional hyperemia in this
ex vivo preparation. Previous work (Metea and Newman, 2006)
has demonstrated that NO, the product of iNOS, inhibits light-
evoked vasodilations in healthy retinas. Together, these results
stronglysuggestthatAGfunctionstoreversethelossof functional
hyperemia by inhibiting iNOS and lowering NO.
The loss of functional hyperemia could be due to a decrease
in light-evoked neuronal activity. However,our ERG experiments
suggest that light-evoked neuronal activity was not diminished in
ourdiabeticanimals.Severalpreviousanimalstudieshavedemon-
strated a decrease in ERG amplitude in early stages of diabetic
retinopathy(Barberetal.,1998;Phippsetal.,2004;Antonettietal.,
2006; Fletcher et al., 2007). There are a number of reasons why
ourERGresultsmightdifferfromtheseearlierstudies.ManyERG
studieshavebeenconductedusingalbinostrainswhoseretinasare
susceptible to light damage, compounding the effects of diabetic
retinopathy. Our experiments are conducted in pigmented Long–
Evansrats,astrainthatdisplaysamuchlowerretinalinﬂammatory
response up to 4months after induction of diabetes by streptozo-
tocin, compared to changes observed in albino Sprague-Dawley
retinas (Kirwin et al.,2009). We also treated our rats with supple-
mental insulin, which could slow the loss of the ERG in diabetic
animals.
The reduced ﬂicker-induced vasodilation we observed could
also be due to a loss of vascular responsiveness. This does not
appear to be the case. A recent study demonstrated that vas-
cular reactivity to exogenous NO stimulation is unchanged in
diabetic patients (Pemp et al., 2009). In addition, we demon-
strated in an earlier study using the ex vivo retina preparation that
prostaglandin E2-induced dilation of retinal arterioles remains
unchanged in diabetic animals (Mishra and Newman, 2010). The
decrease in ﬂicker-induced vasodilation could also be due to an
increase in the resting diameter of the vessels. However, there was
no signiﬁcant difference in resting diameter in control and dia-
betic groups, and the reduced dilation in diabetic animals was
independent of resting vessel diameter (Figure 3C).
Instead,the loss of ﬂicker-induced vasodilation is likely caused
by altered neurovascular coupling in diabetic retinas. Recent evi-
dence suggests that ﬂicker-induced vasodilation in the retina as
well as neuronal activity-dependent vasodilation in the brain, is
largely mediated by glial cells. Release of transmitters from active
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FIGURE 3 |Aminoguanidine treatment reversed the loss of
ﬂicker-induced arteriole dilation in diabetic animals. (A)The reduction in
ﬂicker-induced vasodilation in diabetic animals was restored by treatment with
AG (either IV or in H2O). (B)The resting arteriole diameter was similar in all
experimental groups. (C)The amplitude of ﬂicker-evoked dilation in diabetic
animals was independent of resting arteriole diameter. +Indicates mean
values for the control and diabetic groups. (D) AG did not alter ﬂicker-induced
vasodilations in control animals. (E) AG did not alter the resting arteriole
diameter in control animals. Numbers in parenthesis indicate number of
animals. *Indicates P <0.001.
FIGURE 4 | Electroretinogram recordings from control and
diabetic animals were similar. (A) Intensity series of ERG traces
from a control and a diabetic animal to 10ms light ﬂashes (black bars at
bottom) of increasing intensities (numbers indicate intensity in log
units). (B) Intensity-response relations for the control (open circles)
and diabetic (black squares) series shown in (A). (C,D)The maximum
b-wave response (C) and the light intensity evoking a half-maximal
b-wave response (D) were similar in control and diabetic animals
(P >0.4).The data were ﬁt with the Rushton–Naka relation (Naka and
Rushton, 1966).
neurons induces Ca2+ increases in glial cells that, in turn, release
vasodilatoryagentsontobloodvessels(MeteaandNewman,2006;
Attwell et al., 2010). In the retina, NO modulates this signaling
pathwaybyanas-yetunidentiﬁedmechanism,wherebyhightissue
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NO results in reduced vasodilation and enhanced vasoconstric-
tion (Metea and Newman, 2006). The high NO levels found in
the diabetic retina (Kowluru et al., 2000) due to increased iNOS
expression (Du et al., 2002; Mishra and Newman, 2010) likely
inhibit the glial release of dilatory agents, disrupting the coupling
betweenneuronalactivityandvasodilation.ItislikelythatAGacts
by inhibiting iNOS and lowering retinal NO levels, thus allowing
normal neurovascular signaling to occur. Our ﬁnding that AG
does not alter functional hyperemia in control animals supports
thisview,asiNOSexpressionisminimalinthehealthyretina.The
oxygenation response to carbogen inhalation challenge, another
vascular response that is diminished in diabetic retinas, is also
restored by iNOS inhibitors (Berkowitz et al.,2004).
Light-evoked vasodilation in the retina, as well as neuronal
activity-dependent vasodilation in the brain, is believed to be
importantformeetingtheincreaseddemandof activeneuronsfor
oxygen and glucose (Polak et al.,2002;Riva et al.,2005).A disrup-
tionofthiscouplingmayhavedamagingeffectsduetotheresulting
hypoxia, hypoglycemia, or accumulation of harmful metabolites.
Such adverse effects could potentially be offset by an increase in
resting vessel diameter, and such increases have been reported in
some studies of early stage diabetic retinopathy (Klein et al.,2004;
Royetal.,2011).However,alossof functionalhyperemiahasbeen
reported in diabetic patients who showed no increase in resting
vesseldiameter(Garhoferetal.,2004;Beketal.,2008).Ourresults
also show no increase in resting diameter in diabetic animals at
the 7month post-induction stage. Further research is needed to
determinewhetherthelossoffunctionalhyperemiainthediabetic
retina results in adverse physiological consequences.
Aminoguanidine has been previously assessed as a treatment
for complications of diabetes in both animal models and in
diabetic patients. A clinical study has demonstrated the ben-
eﬁcial effects of AG on retinopathy, where signiﬁcantly fewer
patients showed progression of retinopathy when treated with
AG, compared to placebo-treated patients (Bolton et al., 2004).
Several studies on animal models of diabetes have also demon-
strated the efﬁcacy of iNOS inhibitors in slowing the progression
of diabetic retinopathy (Hammes et al., 1991; Kern et al., 2000;
Kowluru et al., 2000; Kern and Engerman, 2001; Du et al., 2002).
Early treatment with iNOS inhibitors has also been shown to
be more efﬁcacious in slowing the progression of the disease
(Berkowitz et al., 2005). The beneﬁcial effects of AG have gener-
ally been attributed to the inhibition of AGE formation. However,
two studies have shown that AG prevents the development of
diabetic retinopathy without signiﬁcantly affecting AGE produc-
tion (Kern et al., 2000; Kern and Engerman, 2001), suggesting
that the principal action of AG in diabetic retinas is to inhibit
iNOS. Supporting this view, diabetic retinopathy is also reduced
in iNOS-deﬁcient mice (Zheng et al., 2007). It remains to be
determined whether the beneﬁcial effect of iNOS inhibitors is
due to a restoration of functional hyperemia. Targeting iNOS or
its downstream signaling pathway with more selective inhibitors
to reverse the loss of functional hyperemia may help to resolve
this issue and may suggest new therapies for treating diabetic
retinopathy.
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